<p>Nautilus Biotechnology, Inc. 面臨其普通股因未符合最低出價要求而被納斯達克退市的重大風險。這種情況可能會對公司的股權證券銷售能力和股票流動性產生不利影響。儘管公司努力將其上市轉移到納斯達克資本市場，並可能進行反向股票拆分，但並不能保證能夠恢復合規性。退市可能導致市場報價、流動性和交易活動減少，並阻礙未來融資機會。</p>
<p>總體而言，華爾街對 NAUT 股票的共識評級為適度買入，基於 2 個買入評級。</p>
<p>要了解更多關於 Nautilus Biotechnology, Inc. 的風險因素，請點擊這裏。</p>

NAUT

<p>Nautilus Biotechnology, Inc. 面臨因未符合最低出價要求而被納斯達克退市的風險。這可能會影響公司的股權證券銷售能力並減少股票流動性。儘管公司正在考慮轉移至納斯達克資本市場和進行反向股票拆分，但合規性並不保證。退市可能導致市場報價降低，並阻礙未來融資。目前，NAUT 股票在華爾街的共識評級為適度買入，基於 2 個買入評級</p>

<p>Nautilus Biotechnology, Inc. faces a significant risk of its Common Stock being delisted from Nasdaq due to non-compliance with the Minimum Bid Price Requirement. This situation could adversely affect the company’s ability to sell equity securities and the liquidity of its stock. Despite efforts to transfer its listing to the Nasdaq Capital Market and potentially conduct a reverse stock split, there is no assurance of regaining compliance. Delisting could lead to reduced market quotations, liquidity, and trading activity, as well as hinder future financing opportunities.</p>
<div class="lb-trans"><p>Nautilus Biotechnology, Inc. 面臨其普通股因未符合最低出價要求而被納斯達克退市的重大風險。這種情況可能會對公司的股權證券銷售能力和股票流動性產生不利影響。儘管公司努力將其上市轉移到納斯達克資本市場，並可能進行反向股票拆分，但並不能保證能夠恢復合規性。退市可能導致市場報價、流動性和交易活動減少，並阻礙未來融資機會。</p>
</div><p>Overall, Wall Street has a Moderate Buy consensus rating on NAUT stock based on 2 Buys.</p>
<div class="lb-trans"><p>總體而言，華爾街對 NAUT 股票的共識評級為適度買入，基於 2 個買入評級。</p>
</div><p>To learn more about Nautilus Biotechnolgy, Inc.’s risk factors, click here.</p>
<div class="lb-trans"><p>要了解更多關於 Nautilus Biotechnology, Inc. 的風險因素，請點擊這裏。</p>
</div>

Nautilus Biotechnology 因合規性挑戰面臨納斯達克退市的風險